Drug Doubles Survival in Metastatic Pancreatic Cancer Trial

An international clinical trial found that daraxonrasib doubled median survival for patients with metastatic pancreatic cancer when used as a second-line treatment. The final results were presented Sunday at the American Society of Clinical Oncology annual meeting in Chicago. An interim analysis released April 13 had already indicated the same survival benefit.

Wolpin, lead investigator at Dana-Farber Cancer Institute, said pancreatic ductal adenocarcinoma remains among the most challenging cancers with limited therapeutic options. The American pharmaceutical company Revolution Medicines released the data.

France records 16,000 new pancreatic cancer cases each year, with incidence having tripled over the past 20 years. A personalized screening and prevention program launched by the Gustave-Roussy Institute has been extended to eight additional centers. Thomas Pudlarz, head of the pancreatic care pathway in the Interception program at the institute, described the rollout.